A Possible ‘’Functional’’ HIV Cure On The Way
A “functional cure” to HIV may have been discovered by a team of researchers at Hong Kong University’s AIDS Institute.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Vaccine. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Vaccine and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Vaccine?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
The discovery made by Professor Chen Zhiwei demonstrated that the new antibody can help control the virus and eliminate infected cells.
Professor Chen says that the new antibody, which was tested on mice, could be used for both treatment and prevention.
It is hoped that a treatment can be developed to save China from a growing HIV epidemic particularly among high risk groups such as sex workers and men who have sex with men (MSM).
Figures from the UN-supported AIDS Data Hub state that there are around 850,000 people in China infected with HIV.
Currently, HIV treatments are able to suppress the virus via daily oral medication, while this new antibody will be able to be injected quarterly and have the added benefit of eliminating infected cells.
Chen stated that the antibody would be able to treat all varieties of HIV. This will be the first since there is no vaccine to cure different types of HIV viruses.
“For our newly discovered bispecific antibody, it works for all of them, so that’s the major difference,” Chen told Reuters.
Professor Chen’s goal is to bring the antibody into clinical trials and would allow 3-5 years of thorough study.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
